Skip to main content
Log in

Nonlinear mixed effect modeling of the pharmacodynamics of natriuretic peptides in rats

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

Natriuretic peptides have not only natriuretic/diuretic but also hypotensive activities, and the decreased renal perfusion caused by the excessive hypotension is known to attenuate the diuretic actions. The present study was designed to examine the relationship between the dosing (intravenous constant infusion) rates and the diuretic actions of α-rat atrial natriuretic peptide (α-rANP) and rat brain natriuretic peptide (rBNP) in rats, and population (nonlinear mixed effect model) analysis was applied to these complicated diuretic actions. The intrinsic diuretic activities of α-rANP and rBNP could be analyzed, and the effects of blood pressure, heart rate, and also inhibition of degradation enzyme on the diuresis of natriuretic peptides were estimated simultaneously. The population analysis was useful for analyzing such pharmacodynamic data for which the individual analysis could not be applied easily.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Y. Saito, K. Nakao, K. Nishimura, A. Sugawara, K. Okumura, K. Obata, R. Sonoda, T. Ban, H. Yasue, and H. Imura. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function.Circulation 76:115–124 (1987).

    Article  CAS  PubMed  Google Scholar 

  2. T. D. Giles, A. C. Quiros, L. E. Roffidal, H. Marder, and G. E. Sander. Prolonged hemodynamic benefits from a high-dose bolus injection of human atrial netriuretic factor in congestive heart failure.Clin. Pharmacol. Ther. 50:557–563 (1991).

    Article  CAS  PubMed  Google Scholar 

  3. P. Needleman, E. H. Blaine, J. E. Greenwald, M. L. Michener, C. B. Saper, P. T. Stockmann, and H. E. Tolunary. The biochemical pharmacology of atrial peptides.Ann. Rev. Pharmacol. Toxicol. 29:23–54 (1989).

    Article  CAS  Google Scholar 

  4. E. H. Blaine, Atrial natriuretic factor plays a significant role in body fluid homeostasis.Hypertension 15:2–8 (1990).

    Article  CAS  PubMed  Google Scholar 

  5. T. Sudoh, K. Kangawa, N. Minamino, and H. Matsuo. A new natriuretic peptide in porcine brain.Nature 332:78–81 (1988).

    Article  CAS  PubMed  Google Scholar 

  6. Y. Saito, K. Nakao, H. Itoh, I. Yamada, M. Mukoyama, K. Arai, K. Hosoda, G. Shirakami, S. Suga, N. Minamino, K. Kangawa, H. Matsuo, and H. Imura. Brain natriuretic peptide is a novel cardiac hormone.Biochem. Biophys. Res. Commun. 161:732–739 (1989).

    Article  PubMed  Google Scholar 

  7. Y. Ogawa, K. Nakao, M. Mukoyama, G. Shirakami, H. Itoh, K. Hosoda, Y. Saito, H. Arai, S. Suga, M. Jougasaki, T. Yamada, Y. Kambayashi, K. Inouye, and H. Imura. Rat brain natriuretic peptide-tissue distribution and molecular form.Endocrinology 126:2225–2227 (1990).

    Article  CAS  PubMed  Google Scholar 

  8. Y. Kambayashi, K. Nakao, M. Mukoyama, Y. Saito, Y. Ogawa, S. Shiono, K. Inouye, N. Yoshida, and H. Imura. Isolation and sequence determination of human brain natriuretic peptide in human atrium.FEBS Lett. 259:341–345 (1990).

    Article  CAS  PubMed  Google Scholar 

  9. S. L. Beal and L. B. Sheiner (eds.).NONMEM Users Guides, NONMEM Project Group, University of California at San Francisco, San Francisco, 1989.

    Google Scholar 

  10. L. B. Sheiner and T. M. Ludden. Population pharmacokinetics/dynamics.Ann. Rev. Pharmacol. Toxicol. 32:185–209 (1992).

    Article  CAS  Google Scholar 

  11. A. J. Kenny and A. L. Stephenson. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide.FEBS Lett. 232:1–8 (1988).

    Article  CAS  PubMed  Google Scholar 

  12. R. L. Webb, G. D. Yasay, C. McMartin, R. B. McNeal, and M. B. Zimmerman. Degradation of atrial natriuretic peptide: pharmacologie effects of protease EC 24.11 inhibition.J. Cardiovasc. Pharmacol. 14:285–293 (1989).

    Article  CAS  PubMed  Google Scholar 

  13. Y. Kambayashi, K. Nakao, H. Kimura, T. Kawabata, M. Nakamura, K. Inouye, N. Yoshida, and H. Imura. Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP.Biochem. Biophys. Res. Commun. 173:599–605 (1990).

    Article  CAS  PubMed  Google Scholar 

  14. M. Yoshimura, H. Yasue, E. Morita, N. Sakaino, M. Jougasaki, M. Kurose, M. Mukoyama, Y. Saito, K. Nakao, and H. Imura. Hemodynamic, renal and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.Circulation 84:1581–1588 (1991).

    Article  CAS  PubMed  Google Scholar 

  15. Y. Hashimoto, K. Nakao, N. Hama, M. Mukoyama, H. Imura, M. Yasuhara, and R. Hori. Pharmacokinetics of brain natriuretic peptide in rats.Chem. Pharm. Bull. 40:1650–1652 (1992).

    Article  CAS  PubMed  Google Scholar 

  16. M. R. Wilkins, S. L. Settle, and P. Needleman. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3′, 5′-cyclic monophosphate degradation.J. Clin. Invest. 85:1274–1279 (1990).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. M. Chinkers, D. L. Garbers, M. S. Chang, D. G. Lowe, H. Chin, and D. V. Schulz. A membrane form of guanylate cyclase is an atrial natriuretic receptor.Nature 338:78–83 (1989).

    Article  CAS  PubMed  Google Scholar 

  18. K. J. Koller, D. G. Lowe, G. L. Bennett, N. Minamino, K. Kangawa, H. Matsuo, and D. V. Goeddel. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP).Science 252:120–123 (1991).

    Article  CAS  PubMed  Google Scholar 

  19. S. Suga, K. Nakao, K. Hosoda, M. Mukoyama, Y. Ogawa, G. Shirakami, H. Arai, Y. Saito, Y. Kambayashi, K. Inouye, and H. Imura. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.Endocrinology 130:229–239 (1992).

    CAS  PubMed  Google Scholar 

  20. N. Yokota, Y. Yamamoto, M. Aburaya, K. Kitamura, T. Eto, K. Kangawa, N. Minamino, H. Matsuo, and K. Tanaka. Increased secretion of brain natriuretic peptide and atrial natriuretic peptide, but not sufficient to induce natriuresis in rats with nephrotic syndrome.Biochem. Biophys. Res. Commun. 174:128–135 (1991).

    Article  CAS  PubMed  Google Scholar 

  21. T. Maack, M. Suzuki, F. A. Almeida, D. Nussenzveig, R. M. Scarborough, G. A. McEnroe, and J. A. Lewicki. Physiological role of silent receptors of atrial natriuretic factor.Science 238:675–678 (1987).

    Article  CAS  PubMed  Google Scholar 

  22. G. M. Olins, P. A. Krieter, A. J. Trapani, K. L. Spear, and P. R. Bovy. Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptide in vitro and in vivo.Mol. Cell. Endocrinol. 61:201–208 (1989).

    Article  CAS  PubMed  Google Scholar 

  23. M. R. Wilkins, S. L. Settle, P. T. Stockmann, and P. Needleman. Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure.Proc. Natl. Acad. Sci. U.S.87:6465–6469 (1990).

    Article  CAS  Google Scholar 

  24. A. A. Seymour, M. M. Asaad, B. E. Abboa-Offei, P. L. Rovnyak, S. Fennell, and W. L. Rogers. Potentiation of brain natriuretic peptide by SQ28603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats.J. Pharmacol. Exp. Ther. 262:60–70 (1992).

    CAS  PubMed  Google Scholar 

  25. C. C. Lang, J. G. Motwani, W. J. R. Coutie, and A. D. Struthers. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism.Clin. Sci. 82:619–623 (1992).

    CAS  PubMed  Google Scholar 

  26. M. Gagelmann, D. Hock, and W. G. Frossmann. Urodilatin (CDD/ANP95-126) is not biologically inactivated by a peptidase from dog kidney membrane in contrast to atrial natriuretic peptide/cardiodilatin (α-hANP/CDD99-126).FEBS Lett. 233:249–254 (1988).

    Article  CAS  PubMed  Google Scholar 

  27. J. A. Norman, D. Little, M. Bolgar, and D. Donata. Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry.Biochem. Biophys. Res. Commun. 175:22–30 (1991).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hashimoto, Y., Mori, S., Hama, N. et al. Nonlinear mixed effect modeling of the pharmacodynamics of natriuretic peptides in rats. Journal of Pharmacokinetics and Biopharmaceutics 21, 281–297 (1993). https://doi.org/10.1007/BF01059780

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01059780

Key words

Navigation